Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × AST5902 × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm, Residual 1 Adenocarcinoma of Lung 1

Interventions

osimertinib 1 durvalumab 1 anlotinib 1 aflutinib 1 Radiosurgery 1 Monatide (IMS 3015) 1 Immunotherapy 1 Docetaxel 1 Circulating Tumor DNA 1 Chemotherapy, Adjuvant 1 Biological Assay 1 Adjuvants, Pharmaceutic 1 AST5902 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Peking University People's Hospital

Phase 1/2 Unknown

Adenocarcinoma of Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡